

Cite this: *Chem. Sci.*, 2018, 9, 2927

ROS scavenging Mn₃O₄ nanozymes for *in vivo* anti-inflammation†

Jia Yao,^a Yuan Cheng,^a Min Zhou,^a Sheng Zhao,^a Shichao Lin,^a Xiaoyu Wang,^a Jiangjixing Wu,^a Sirong Li^a and Hui Wei *^{ab}

Reactive oxygen species (ROS)-induced oxidative stress is linked to various diseases, including cardiovascular disease and cancer. Though highly efficient natural ROS scavenging enzymes have been evolved, they are sensitive to environmental conditions and hard to mass-produce. Therefore, enormous efforts have been devoted to developing artificial enzymes with ROS scavenging activities. Among them, ROS scavenging nanozymes have recently attracted great interest owing to their enhanced stability, multi-functionality, and tunable activity. It has been implicated that Mn-contained nanozymes would possess efficient ROS scavenging activities, however only a few such nanozymes have been reported. To fill this gap, herein we demonstrated that Mn₃O₄ nanoparticles (NPs) possessed multiple enzyme mimicking activities (*i.e.*, superoxide dismutase and catalase mimicking activities as well as hydroxyl radical scavenging activity). The Mn₃O₄ nanozymes therefore significantly scavenged superoxide radical as well as hydrogen peroxide and hydroxyl radical. Moreover, they were not only more stable than the corresponding natural enzymes but also superior to CeO₂ nanozymes in terms of ROS elimination. We showed that the Mn₃O₄ NPs not only exhibited excellent ROS removal efficacy *in vitro* but also effectively protected live mice from ROS-induced ear-inflammation *in vivo*. These results indicated that Mn₃O₄ nanozymes are promising therapeutic nanomedicine for treating ROS-related diseases.

Received 27th December 2017

Accepted 15th February 2018

DOI: 10.1039/c7sc05476a

rsc.li/chemical-science

Introduction

Inflammation has been demonstrated to cause various diseases, such as rheumatoid arthritis,¹ cardiovascular diseases,² and even cancer.³ It has been established that the dysregulation of highly active reactive oxygen species (ROS), including superoxide radical ([•]O₂⁻), hydrogen peroxide (H₂O₂) and hydroxyl radical ([•]OH), plays very important roles in these diseases.⁴ The dysregulated ROS can lead to oxidative stress, causing harm to biomolecules like DNA, proteins and lipids.^{5,6} Therefore, live organisms have evolved a number of antioxidant enzymes to scavenge ROS and protect tissues from inflammation-induced damages.^{7,8} Among them, superoxide dismutase (SOD) catalyzes the dismutation of [•]O₂⁻ to H₂O₂. Subsequently, catalase catalyzes the reduction of H₂O₂ to water.⁹ Though ROS scavenging natural enzymes work efficiently to combat inflammation, they are sensitive to environmental conditions (such as

temperature and pH value) and hard to mass-produce.¹⁰ Therefore, intensive efforts have been made to develop ROS scavenging artificial enzymes to overcome the inherent drawbacks of the natural enzymes.^{11,12}

In last decades, catalytic nanomaterials with natural enzyme-like activities (termed as nanozymes) have been developed as emerging artificial enzymes.^{13–31} Nanozymes have many advantages, such as excellent thermal and biological stability, multi-functionality, ease-of-preparation, and tunable activity.^{13,32–34} Among these developed nanozymes, a variety of nanomaterials with ROS scavenging activities have been reported.^{35–38} For instance, ceria nanoparticles (CeO₂ NPs) have been demonstrated to possess SOD mimicking activities due to the mixed valance states of Ce³⁺ and Ce⁴⁺.³⁵ Nevertheless, the ROS scavenging capability of most nanozymes is moderate. Therefore, numerous strategies have been proposed to design more active nanozymes. One possible strategy is adding dopant ions (such as Zr⁴⁺) into ceria NPs to modulate the ratio of Ce³⁺/Ce⁴⁺.³⁹ The superoxide scavenging activity of ceria NPs could also be enhanced through an electron transfer strategy.⁴⁰ On the other hand, pharmacokinetic studies revealed that natural Mn SOD is superior to Cu/Zn SOD and Fe SOD for chronic diseases treatment,⁴¹ which inspires a long effort to synthesize Mn based SOD mimics.⁴² Despite of the great promise, only a few Mn-based nanozymes with antioxidant activities have been developed so far.^{43–45} A very recent study reported the antioxidant activities of

^aDepartment of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures, Nanjing University, Nanjing, Jiangsu 210093, China. E-mail: weihui@nju.edu.cn; Web: <http://weilab.nju.edu.cn>; Fax: +86-25-83594648; Tel: +86-25-83593272

^bState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Collaborative Innovation Center of Chemistry for Life Sciences, Nanjing University, Nanjing, Jiangsu 210023, China

† Electronic supplementary information (ESI) available: Additional figures and associated discussions. See DOI: 10.1039/c7sc05476a



flower-like manganese oxide NPs and applied them for cellular protection *in vitro*.⁴⁵ However, Mn-based nanozymes have not been explored for *in vivo* anti-inflammation yet.

To fill this gap, here we demonstrated that Mn₃O₄ NPs synthesized *via* a hydrothermal method possessed remarkable SOD mimicking activities, thanks to the double oxidation states of Mn²⁺ and Mn³⁺. Thus, the Mn₃O₄ NPs could be used to eliminate [•]O₂⁻ by the disproportionation of [•]O₂⁻ into H₂O₂ and O₂. Besides, the Mn₃O₄ NPs were also capable to catalyze the elimination of H₂O₂ and scavenge [•]OH. Notably, the ROS scavenging capacity of Mn₃O₄ NPs was superior to CeO₂ NPs, which promoted us to further apply them to eliminate ROS both *in vitro* and *in vivo*. We showed that the Mn₃O₄ NPs not only exhibited excellent ROS removal efficacy *in vitro* but also effectively protected live mice from ROS-induced ear-inflammation *in vivo*.

Results and discussion

Synthesis and characterization of Mn₃O₄ NPs

The Mn₃O₄ NPs were synthesized by a hydrothermal method.⁴⁶ TEM and XRD techniques were employed to analyze the morphology and the phase composition of Mn₃O₄ NPs. As presented in Fig. 1A and S1A,[†] the Mn₃O₄ NPs were uniform polyhedrons with an average size of 7–8 nm. Dynamic lighting scattering (DLS) (Fig. S2[†]) and zeta potential (Fig. S3[†]) results of the newly-prepared and two-month stored Mn₃O₄ NPs demonstrated their good long-term storage stability. The lattice shown in TEM agreed well with $d_{[101]} = 0.492$ nm, demonstrating highly crystalline nature of the as-prepared Mn₃O₄ NPs. The XRD pattern of Mn₃O₄ NPs was shown in Fig. 1B. All the measured diffraction peaks matched well to the standard pattern of hausmannite Mn₃O₄ [JCPDS card No. 24-0734, *I*_{41/amd (141)], confirming their highly crystalline nature. As catalytic reactions happened on the surface of NPs, the surface of Mn₃O₄ NPs was further characterized by X-ray photoelectron spectroscopy (XPS) (Fig. S4[†]). Mn 2p_{3/2} and 2p_{1/2} peaks were centered at 641.7 eV and 653.5 eV, respectively. The area ratio (*i.e.*, molar ratio) of Mn²⁺ and Mn³⁺ was about 1 : 2, which agreed well with the theoretical value.}

SOD mimicking activity of Mn₃O₄ NPs

Since [•]O₂⁻ is one of the most destructive ROS, scavenging [•]O₂⁻ by Mn₃O₄ NPs was first investigated. Such [•]O₂⁻ scavenging activity could be attributed to the SOD mimicking activity of Mn₃O₄ NPs. First, [•]O₂⁻ was generated by the reaction of xanthine and xanthine oxidase. Then the ability of Mn₃O₄ NPs to scavenge [•]O₂⁻ was characterized by a [•]O₂⁻ specific probe hydroethidium (HE). HE could react with [•]O₂⁻ to produce fluorescent ethidium, which emitted strong fluorescence centered at 610 nm (Fig. 2A, red line). In the presence of Mn₃O₄ NPs, the fluorescent intensity was significantly reduced (Fig. 2A, blue line) compared with the red line, which illustrated the efficient elimination of [•]O₂⁻ by Mn₃O₄ NPs. The SOD-like catalytic activity of Mn₃O₄ NPs was dose-dependent, and the [•]O₂⁻ scavenging efficiency reached almost 75% when the concentration of Mn₃O₄ NPs was 20 μg mL⁻¹. This result was comparable with that using 1 U mL⁻¹ natural SOD (Fig. 2B), indicating the excellent SOD-like activity of Mn₃O₄ NPs. Besides, when compared with the most widely used SOD mimicking CeO₂ nanozymes (Fig. S1B[†]), the Mn₃O₄ NPs exhibited 1.5-fold enhancement than CeO₂ NPs under the same experimental condition (Fig. 2B). Moreover, Mn₃O₄ NPs showed better thermal stability than natural SOD (Fig. S5[†]). Mn₃O₄ NPs also possessed high SOD mimicking activities over a broad temperature range (from 20 to 60 °C), which has not been achieved for natural SOD (Fig. S6[†]). Two-month stored Mn₃O₄ NPs showed almost the same SOD mimicking activity as the newly-prepared NPs (Fig. S7[†]). In addition, the scavenging of [•]O₂⁻ with Mn₃O₄ NPs was further confirmed by EPR with 5,5-dimethyl-1-pyridine N-oxide (DMPO) as a spin trap. As shown in Fig. S8,[†] the DMPO/[•]OOH signal decreased with the increase of the concentration of Mn₃O₄ NPs, indicating the ability of Mn₃O₄ NPs to eliminate [•]O₂⁻. These results illuminated that the Mn₃O₄ NPs showed significant SOD-like catalytic activity and high stability.

Catalase mimicking activity of Mn₃O₄ NPs

As H₂O₂ is the product of [•]O₂⁻, another important ROS, the H₂O₂ elimination capacity of Mn₃O₄ NPs was also tested. As




Fig. 1 (A) TEM image of Mn₃O₄ NPs. (B) Powder X-ray diffraction pattern of Mn₃O₄ NPs (the red lines at the bottom mark the reference pattern of hausmannite Mn₃O₄ from the JCPDS database, card no. 24-0734).



Fig. 2 (A) Fluorescent spectra of HE after reaction with X and XO, in the absence and presence of Mn₃O₄ NPs. X for xanthine and XO for xanthine oxidase, respectively. (B) Dependence between the elimination of [•]O₂⁻ and concentrations of Mn₃O₄ NPs, CeO₂ NPs, and natural SOD.



shown in Fig. 3A, terephthalic acid (TA) reacted with H_2O_2 to produce 2-hydroxyterephthalic acid with a fluorescent peak at 425 nm. In the presence of Mn_3O_4 NPs, the fluorescent intensity significantly decreased, illustrating the H_2O_2 elimination activity (*i.e.*, the catalase-like activity) of Mn_3O_4 NPs. The catalase-like of Mn_3O_4 NPs was concentration dependent, and about 75% of H_2O_2 was eliminated by using $20 \mu\text{g mL}^{-1}$ Mn_3O_4 NPs, which was even more efficient than that using 10 U mL^{-1} catalase. Besides, Mn_3O_4 NPs also showed better thermal stability than natural catalase (Fig. S10[†]). The H_2O_2 elimination capacity of Mn_3O_4 NPs was also higher than that of CeO_2 NPs (Fig. 3B). In addition, the elimination of H_2O_2 with Mn_3O_4 NPs was also studied by monitoring the absorbance of H_2O_2 at 240 nm (Fig. S11[†]). Both the fluorescence and absorption spectra confirmed that Mn_3O_4 NPs could also eliminate H_2O_2 and possessed superior catalase mimicking property.

Hydroxyl radical scavenging activity of Mn_3O_4 NPs

$\cdot\text{OH}$ is another important ROS, therefore its scavenging would help to protect cells or live organisms from ROS-induced damages more efficiently. To check whether the Mn_3O_4 NPs could also eliminate $\cdot\text{OH}$, both absorption and EPR spectra were applied to detect $\cdot\text{OH}$ level in the presence of Mn_3O_4 NPs. Fenton reaction with the $\text{Fe}^{2+}/\text{H}_2\text{O}_2$ system was used to produce $\cdot\text{OH}$. First, the generated $\cdot\text{OH}$ was detected by its specific probe salicylic acid (SA). As shown in Fig. 4A, an obvious absorption peak at 510 nm was observed after mixing SA with $\text{Fe}^{2+}/\text{H}_2\text{O}_2$. The absorption intensity decreased significantly after adding Mn_3O_4 NPs, which proved the $\cdot\text{OH}$ scavenging activity of Mn_3O_4 NPs. Fig. 4B showed that the elimination of $\cdot\text{OH}$ was enhanced with the increase of the NPs concentration. Nearly 70% elimination was achieved with $10 \mu\text{g mL}^{-1}$ of Mn_3O_4 NPs. We also compared Mn_3O_4 NPs with CeO_2 NPs, demonstrating the higher $\cdot\text{OH}$ scavenging activity of Mn_3O_4 NPs (Fig. 4B). In addition, the $\cdot\text{OH}$ scavenging activity of Mn_3O_4 NPs was further confirmed by EPR. The signal of DMPO/ $\cdot\text{OH}$ decreased with the increase of Mn_3O_4 concentration, which was attributed to the scavenging of $\cdot\text{OH}$ (Fig. S12[†]). All the above results clearly demonstrated the highly efficient ROS scavenging activity of Mn_3O_4 NPs, which was better than the most widely used CeO_2 nanozymes.



Fig. 3 (A) Fluorescent spectra of TA after reaction with H_2O_2 , in the absence and presence of Mn_3O_4 NPs. (B) Dependence between the elimination of H_2O_2 and concentrations of Mn_3O_4 NPs, CeO_2 NPs, and natural catalase.



Fig. 4 (A) Absorption spectra of SA after reaction with $\text{Fe}^{2+}/\text{H}_2\text{O}_2$, in the absence and presence of Mn_3O_4 NPs. SA alone, and SA reacted with Fe^{2+} or H_2O_2 were used as control. (B) Dependence between the elimination of $\cdot\text{OH}$ and concentration of Mn_3O_4 NPs and CeO_2 NPs (mean \pm S.D., ** $p < 0.05$; n.s., not significant).

Intracellular ROS scavenging detection

After demonstrating the scavenging abilities of Mn_3O_4 NPs toward $\cdot\text{O}_2^-$, H_2O_2 , and $\cdot\text{OH}$, the intracellular ROS scavenging activity of Mn_3O_4 NPs was then investigated using Hela cell line as a model. First, the toxicity of Mn_3O_4 NPs was evaluated. The MTT results showed that the Mn_3O_4 NPs exhibited no obvious cytotoxicity within the experimental conditions (Fig. 5A). Then the intracellular ROS level was monitored using 2',7'-dichlorofluorescein diacetate (DCFH-DA) as the fluorescent probe.⁴⁷ As shown in Fig. 5B, the treatment with Rosup resulted in remarkable fluorescent enhancement by laser confocal fluorescence imaging, which corresponded to the increased ROS level in the Hela cells. When the Mn_3O_4 NPs were added, the fluorescence decreased obviously. And the more NPs were added, the more fluorescence decreased, which indicated the dose dependent intracellular ROS scavenging activities of Mn_3O_4 NPs (Fig. 5B and C).

In vivo anti-inflammation

Encouraged by the above cellular results, an ear inflammation model was established to evaluate the anti-inflammation activity of Mn_3O_4 NPs *in vivo*. As displayed in Fig. S13,[†] the right ear of an experimental mouse appeared red and swollen after the topical application of phorbol 12-myristate 13-acetate (PMA) for 6 h, indicating a typical characteristic of inflammation. In order to study the *in vivo* ROS scavenging capability of Mn_3O_4 NPs, the inflamed ears were thereafter subcutaneously treated with Mn_3O_4 NPs at the dose of $0.5 \mu\text{g kg}^{-1}$ and $1.25 \mu\text{g kg}^{-1}$ for each mouse, respectively. As demonstrated in Fig. 6A and B, no obvious fluorescence was observed for mice after treatment with DCFH-DA or PMA only. In contrast, a strong fluorescence was observed in the PMA/DCFH-DA-treated ear (Fig. 6C), which indicated the elevated level of ROS due to the PMA induced inflammation. After treatment with Mn_3O_4 NPs, the fluorescence in the inflamed ear decreased obviously (Fig. 6D, E, and S14[†]). Hematoxylin and eosin (H&E) stained images of PMA induced inflammation ear were also obtained. As shown in Fig. S15B,[†] lymphocytes infiltration was observed obviously compared with the healthy mouse ear (Fig. S15A[†]).






Fig. 5 (A) HeLa cell viability under different concentrations of Mn_3O_4 NPs. (B) Laser confocal fluorescence images of HeLa cells with different treatments: (a–d) 0.01 mM DCFH-DA, (e–h) Rosup and DCFH-DA, (i–l) Rosup and DCFH-DA with $5 \mu\text{g mL}^{-1}$ Mn_3O_4 NPs, (m–p) Rosup and DCFH-DA with $10 \mu\text{g mL}^{-1}$ Mn_3O_4 NPs. (C) Corresponding fluorescent intensity of DCFH-DA in panel (B).




Fig. 6 *In vivo* fluorescence imaging of mice with PMA-induced ear inflammation after treatment with (A) PMA, (B) DCFH-DA, (C) PMA and DCFH-DA, (D) PMA and DCFH-DA with $0.5 \mu\text{g kg}^{-1}$ Mn_3O_4 NPs, and (E) PMA and DCFH-DA with $1.25 \mu\text{g kg}^{-1}$ Mn_3O_4 NPs.

After treatment with Mn_3O_4 NPs, the symptom was alleviated (Fig. S15C and D†). Besides, as shown in Fig. S16,† H&E stained histology section of liver, spleen, and kidney demonstrated negligible toxicity of Mn_3O_4 NPs toward live tissues. These results indicated that the Mn_3O_4 NPs possessed efficient ROS scavenging capacity toward ear inflammation in live mice with safety.

Conclusions

In summary, we synthesized Mn_3O_4 nanozymes with excellent ROS scavenging activity. Due to the SOD mimicking activity, they eliminated as much as nearly 75% $\cdot\text{O}_2^-$, which was superior to CeO_2 NPs. Besides, the Mn_3O_4 NPs could also catalyze the elimination of another two important ROS of H_2O_2 and $\cdot\text{OH}$. *In vitro* experiments showed that the Mn_3O_4 NPs significantly

scavenged intracellular ROS. Due to their excellent antioxidant activities *in vitro*, an inflammation model was established to evaluate the ROS scavenging ability of Mn_3O_4 NPs *in vivo*. The Mn_3O_4 NPs efficiently relieved the PMA-induced ear inflammation in live mice. This work not only demonstrated that Mn_3O_4 nanozymes possessed ROS scavenging activities, but also provided a promising therapeutic strategy for inflammation by using redox active nanozymes.

Experimental

Chemicals and materials

Manganese acetate ($\text{Mn}(\text{OAc})_2$) was purchased from Shanghai Meixing Chemical Reagent Co., Ltd. Hydrogen peroxide (H_2O_2 , 30%) was obtained from Sinopharm Chemical Reagent Co., Ltd. Xanthine, xanthine oxidase, SOD from bovine erythrocytes, and phorbol 12-myristate 13-acetate (PMA) were supplied by Sigma-Aldrich. 2',7'-Dichlorofluorescein diacetate (DCFH-DA) and Rosup were purchased from Beyotime Chemical Reagent Co., Ltd. 5,5-Dimethyl-1-pyridine N-oxide (DMPO) was from Nanjing Tongquan Chemical Reagent Co., Ltd. Hydroethidine (HE), salicylic acid (SA), and terephthalic acid (TA) were from Aladdin Chemical Reagent Co., Ltd. All chemical reagents were used as received without any further purification. All aqueous solutions were prepared with deionized water ($18.2 \text{ M}\Omega \text{ cm}$, Millipore).

Instrumentation

Transmission electron microscopy (TEM) images were obtained on a JEM-2100 microscope (JEOL, Japan) at an acceleration voltage of 200 kV. Powder X-ray diffraction (XRD) data was collected on a Rigaku Ultima diffractometer by using $\text{Cu K}\alpha$ radiation. The diffractometer was operated at 40 kV and 40 mA



with a scan rate of 5° min^{-1} . Dynamic lighting scattering (DLS) and zeta potential distribution were measured on a Nanosizer ZS90 (Malvern). X-ray photoelectron spectroscopy (XPS) was collected using a PHI 5000 VersaProbe (Ulvac-Phi, Japan). All the measurements were carried out with reference to C 1s binding energy (285 eV) as the internal standard. UV-visible absorption spectra were recorded using a TU-1900 spectrophotometer (Beijing Purkinje General Instrument Co. Ltd., China). Nitrogen adsorption-desorption isotherms were measured at 77 K using a Quantachrome Autosorb-IQ-2C-TCD-VP analyzer, which were used to calculate the surface areas of the nanoparticles with the Brunauer-Emmett-Teller (BET) method. Photoluminescence spectra were measured on a Hitachi F-4600 spectrometer (Hitachi Co. Ltd., Japan). Electron paramagnetic resonance (EPR) detection was carried out in an EMX-10/12 EPR spectrometer (Bruker, Germany). A confocal laser scan microscopy was used for cell imaging, which consists of an epifluorescent microscope (IX-83, Olympus, with halogen lamp as the light source), a spinning disk confocal system (Andor), and an electron multiplying charge-coupled device (EMCCD) camera (Evolve 512, Photometrics). The *in vivo* fluorescence imaging of live mice was recorded on a PerkinElmer *In vivo* Imaging System with an excitation wavelength of 465 nm and an emission wavelength of 520 nm.

Synthesis of Mn_3O_4 NPs

The Mn_3O_4 NPs were synthesized as follows.⁴⁶ In a typical procedure, 1.225 g $\text{Mn}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ was dissolved in 60 mL anhydrous ethanol and magnetically stirred until fully dissolved. Then the mixture was transferred into a 100 mL Teflon-lined stainless steel autoclave for thermal treatment for 24 h at 120°C . The products were washed by deionized water for three times after cooling down to room temperature, and the dark-brown precipitate was obtained.

Synthesis of CeO_2 NPs

The CeO_2 NPs were synthesized according to our previous work.⁴⁸

SOD-like activity of Mn_3O_4 NPs

The SOD-like catalytic activity of Mn_3O_4 NPs was evaluated *via* two methods. Both of them monitored the amount of $\cdot\text{O}_2^-$ scavenged. The more $\cdot\text{O}_2^-$ scavenged, the higher SOD-like activity of Mn_3O_4 NPs was.

Method one. The amount of $\cdot\text{O}_2^-$ scavenged was indirectly detected by measuring the fluorescent intensity of ethidium, which was the oxidation product of HE by $\cdot\text{O}_2^-$. First, $\cdot\text{O}_2^-$ was generated by mixing xanthine (0.6 mM) and xanthine oxidase (0.05 U mL^{-1}) in phosphate buffer (0.1 M, pH 7.4) at 37°C .⁴⁹ After 40 min, the Mn_3O_4 NPs were added to the solution for another 40 min reaction, followed by adding HE (0.5 mg mL^{-1}). Then the solution was vortexed and left undisturbed for 40 min before fluorescence measurement. Ethidium was excited at 470 nm and emitted at 610 nm. The scavenging percentage of $\cdot\text{O}_2^-$ was calculated according to the following equation: elimination (%) = $[(F_0 - F)/F_0] \times 100\%$, where F_0 and F were the

fluorescent intensities of ethidium in the absence and presence of Mn_3O_4 NPs, respectively.

CeO_2 NPs and natural SOD were also tested under the same condition for comparison.

Method two. EPR was used to directly detect $\cdot\text{O}_2^-$ scavenging. The Mn_3O_4 NPs were added to the mixture of xanthine and xanthine oxidase to scavenge the generated $\cdot\text{O}_2^-$. DMPO (100 mM) was employed to trap the unscavenged $\cdot\text{O}_2^-$ by forming DMPO/ $\cdot\text{OOH}$. DMSO was also added to enhance the stability of spin adduct.⁵⁰

Catalase-like activity of Mn_3O_4 NPs

The catalase-like activity of Mn_3O_4 NPs was evaluated by monitoring the catalytic elimination of H_2O_2 with Mn_3O_4 NPs using fluorescent and UV-visible absorption spectra.

Fluorescent method. H_2O_2 can decompose into $\cdot\text{OH}$, which would react with TA to produce fluorescent 2-hydroxyterephthalic acid with an excitation wavelength of 320 nm and an emission peak at 425 nm.⁵¹ In the presence of catalase (or catalase mimics), H_2O_2 would decompose into H_2O and O_2 and could not generate fluorescent 2-hydroxyterephthalic acid. Therefore, by monitoring the fluorescent signal of 2-hydroxyterephthalic acid, the elimination of H_2O_2 could be investigated. After phosphate buffer (25 mM, pH 7.4) containing H_2O_2 (10 mM) and different concentrations of Mn_3O_4 NPs was vortexed vigorously and incubated at room temperature for 6 h, TA in DMF (0.5 mM) was added. Then the fluorescence of the mixture was measured.

Absorption method. The elimination of H_2O_2 was also detected by monitoring its characteristic absorbance at 240 nm using UV-visible absorption spectroscopy.

Hydroxyl radical scavenging activity of Mn_3O_4 NPs

The $\cdot\text{OH}$ was generated through Fenton reaction of 1.8 mM FeSO_4 and 5 mM H_2O_2 for 10 min. Two methods were applied to study the $\cdot\text{OH}$ scavenging activity of Mn_3O_4 NPs.

Method one. The amount of $\cdot\text{OH}$ scavenged was detected by measuring the characteristic absorbance of 2,3-dihydroxybenzoic acid at 510 nm, which was produced by reacting SA (1.8 mM) with $\cdot\text{OH}$.

Method two. The scavenging of $\cdot\text{OH}$ was also detected by using EPR. DMPO was used as a spin trap to form DMPO/ $\cdot\text{OH}$ spin adduct, which yielded four characteristic lines with relative intensities of 1 : 2 : 2 : 1.

Cytotoxicity assay

Hela cells were refreshed in high glucose DMEM culture medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin ($10\,000 \text{ U mL}^{-1}$) under the atmosphere of 5% CO_2 at 37°C . For cell viability assay, Hela cells were seeded into 96-well plates with a density of 8×10^3 cells per well. The medium was refreshed after overnight incubation, followed by adding Mn_3O_4 NPs with different concentrations ($0\text{--}10 \mu\text{g mL}^{-1}$). After incubating for another 24 h, the cells were washed by PBS for three times and the cell viability was



determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-*H*-tetrazolium bromide (MTT) assay.

Intracellular ROS scavenging detection

The intracellular level of ROS was monitored by using non-fluorescent DCFH-DA, which could penetrate through the cell membrane into cytosol and be hydrolyzed by intracellular esterase into DCFH. Then DCFH reacted with intracellular free radicals to produce fluorescent product DCF with excitation and emission wavelength at 488 nm and 520 nm, respectively. The whole procedure was performed as below: Hela cells were first seeded into 24-well plates and incubated for 24 h, followed by adding Rosup (0.5 mg mL⁻¹) to produce intracellular ROS. After 30 min, the medium was refreshed three times and then Mn₃O₄ NPs with different concentrations were added for 1 h incubation. Subsequently, DCFH-DA (0.01 mM) in serum-free medium without phenol red was added after the cells were washed by PBS (pH 7.4) in triplicate. Cell nucleus was stained with Hoechst for confocal laser scan microscopy imaging.

In vivo anti-inflammation

All the animal studies were approved by the Committee for Experimental Animals Welfare and Ethics of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. Kunming mice (20 g) were chosen for establishing an inflammation model.⁵² 50 μL of PMA (100 μg mL⁻¹) acetone solution was topically applied on the right ear of each mouse to induce local ear inflammation. After 6 h induction, the mice were anesthetized with chloral hydrate and subcutaneously injected with Mn₃O₄ NPs (at a dose of 0.5 and 1.25 μg kg⁻¹, respectively). After 30 min incubation, 50 μL of DCFH-DA (1 mM) was injected in a similar way. After another 30 min incubation, the whole body fluorescent images were recorded by a PerkinElmer *In vivo* Imaging System with an excitation wavelength of 488 nm and an emission wavelength of 520 nm. Mice without treatment and treated with PMA or DCFH-DA only were used as control.

In vivo toxicity toward live tissues

In vivo toxicity of Mn₃O₄ NPs toward live tissues was evaluated by pathological observation of the tissues (including liver, spleen, and kidney) from the test groups. These tissues were collected and rinsed with deionized water, and then fixed in 10% neutral buffered formalin. The tissues were processed routinely, dried and embedded into paraffin, sectioned at a thickness of 4 mm, stained with hematoxylin and eosin (H&E), examined and photographed by optical microscopy.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by National Natural Science Foundation of China (21722503 and 21405081), Natural Science

Foundation of Jiangsu Province (BK20160615), 973 Program (2015CB659400), PAPD program, Shuangchuang Program of Jiangsu Province, Six Talents Summit Program of Jiangsu Province, Open Funds of the State Key Laboratory of Coordination Chemistry (SKLCC1619), Open Funds of the State Key Laboratory of Analytical Chemistry for Life Science (SKLACLS1704), China Postdoctoral Science Foundation (2016M590437), and Thousand Talents Program for Young Researchers. We thank He Zhang for insightful discussions.

Notes and references

- 1 E. H. Choy and G. S. Panayi, *N. Engl. J. Med.*, 2001, **344**, 907–916.
- 2 A. Taube, R. Schlich, H. Sell, K. Eckardt and J. Eckel, *Am. J. Physiol.: Heart Circ. Physiol.*, 2012, **302**, H2148–H2165.
- 3 F. Colotta, P. Allavena, A. Sica, C. Garlanda and A. Mantovani, *Carcinogenesis*, 2009, **30**, 1073–1081.
- 4 I. Chapple, *J. Clin. Periodontol.*, 1997, **24**, 287–296.
- 5 R. A. Floyd and J. M. Carney, *Ann. Neurol.*, 1992, **32**, S22–S27.
- 6 S. Leutner, A. Eckert and W. Müller, *J. Neural Transm.*, 2001, **108**, 955–967.
- 7 X. Li, P. Fang, J. Mai, E. T. Choi, H. Wang and X.-f. Yang, *J. Hematol. Oncol.*, 2013, **6**, 19.
- 8 H. Guo, J. B. Callaway and J. P. Ting, *Nat. Med.*, 2015, **21**, 677–687.
- 9 J. M. Matés, C. Pérez Gómez and I. N. De Castro, *Clin. Biochem.*, 1999, **32**, 595–603.
- 10 R. Breslow, *Acc. Chem. Res.*, 1995, **28**, 146–153.
- 11 B. J. Day, *Biochem. Pharmacol.*, 2009, **77**, 285–296.
- 12 S. R. Doctrow, K. Huffman, C. B. Marcus, W. Musleh, A. Bruce, M. Baudry and B. Malfroy, *Adv. Pharmacol.*, 1996, **38**, 247–269.
- 13 H. Wei and E. Wang, *Chem. Soc. Rev.*, 2013, **42**, 6060–6093.
- 14 X. Wang, W. Guo, Y. Hu, J. Wu and H. Wei, *Nanozymes: next wave of artificial enzymes*, Springer, 2016.
- 15 F. Manea, F. B. Houillon, L. Pasquato and P. Scrimin, *Angew. Chem., Int. Ed.*, 2004, **43**, 6165–6169.
- 16 J. Chen, S. Patil, S. Seal and J. F. McGinnis, *Nat. Nanotechnol.*, 2006, **1**, 142–150.
- 17 L. Gao, J. Zhuang, L. Nie, J. Zhang, Y. Zhang, N. Gu, T. Wang, J. Feng, D. Yang, S. Perrett and X. Yan, *Nat. Nanotechnol.*, 2007, **2**, 577–583.
- 18 A. Asati, S. Santra, C. Kaitanis, S. Nath and J. M. Perez, *Angew. Chem., Int. Ed.*, 2009, **48**, 2308–2312.
- 19 K. Fan, C. Cao, Y. Pan, D. Lu, D. Yang, J. Feng, L. Song, M. Liang and X. Yan, *Nat. Nanotechnol.*, 2012, **7**, 459–464.
- 20 F. Natalio, R. André, A. F. Hartog, B. Stoll, K. P. Jochum, R. Wever and W. Tremel, *Nat. Nanotechnol.*, 2012, **7**, 530–535.
- 21 C. K. Kim, T. Kim, I. Y. Choi, M. Soh, D. Kim, Y. J. Kim, H. Jang, H. S. Yang, J. Y. Kim, H. K. Park, S. P. Park, S. Park, T. Yu, B. W. Yoon, S. H. Lee and T. Hyeon, *Angew. Chem., Int. Ed.*, 2012, **51**, 11039–11043.
- 22 M. Diez Castellnou, F. Mancin and P. Scrimin, *J. Am. Chem. Soc.*, 2014, **136**, 1158–1161.
- 23 T. Xue, B. Peng, M. Xue, X. Zhong, C. Y. Chiu, S. Yang, Y. Qu, L. Ruan, S. Jiang and S. Dubin, *Nat. Commun.*, 2014, **5**, 3200.



- 24 B. Liu, Z. Sun, P. J. J. Huang and J. Liu, *J. Am. Chem. Soc.*, 2015, **137**, 1290–1295.
- 25 G. Y. Tonga, Y. Jeong, B. Duncan, T. Mizuhara, R. Mout, R. Das, S. T. Kim, Y. C. Yeh, B. Yan, S. Hou and V. M. Rotello, *Nat. Chem.*, 2015, **7**, 597–603.
- 26 W. Zhang, S. Hu, J. J. Yin, W. He, W. Lu, M. Ma, N. Gu and Y. Zhang, *J. Am. Chem. Soc.*, 2016, **138**, 5860–5865.
- 27 H. Cheng, L. Zhang, J. He, W. Guo, Z. Zhou, X. Zhang, S. Nie and H. Wei, *Anal. Chem.*, 2016, **88**, 5489–5497.
- 28 Q. Wang, X. Zhang, L. Huang, Z. Zhang and S. Dong, *Angew. Chem., Int. Ed.*, 2017, **56**, 16082–16085.
- 29 Z. Zhang, X. Zhang, B. Liu and J. Liu, *J. Am. Chem. Soc.*, 2017, **139**, 5412–5419.
- 30 H. Cheng, Y. Liu, Y. Hu, Y. Ding, S. Lin, W. Cao, Q. Wang, J. Wu, F. Muhammad, X. Zhao, D. Zhao, Z. Li, H. Xing and H. Wei, *Anal. Chem.*, 2017, **89**, 11552–11559.
- 31 Y. Hu, H. Cheng, X. Zhao, J. Wu, F. Muhammad, S. Lin, J. He, L. Zhou, C. Zhang, Y. Deng, P. Wang, Z. Zhou, S. Nie and H. Wei, *ACS Nano*, 2017, **11**, 5558–5566.
- 32 Y. Zhou, B. Liu, R. Yang and J. Liu, *Bioconjugate Chem.*, 2017, **28**, 2903–2909.
- 33 X. Wang, Y. Hu and H. Wei, *Inorg. Chem. Front.*, 2016, **3**, 41–60.
- 34 L. Gao, K. Fan and X. Yan, *Theranostics*, 2017, **7**, 3207.
- 35 C. Korsvik, S. Patil, S. Seal and W. T. Self, *Chem. Commun.*, 2007, 1056–1058.
- 36 X. Liu, W. Wei, Q. Yuan, X. Zhang, N. Li, Y. Du, G. Ma, C. Yan and D. Ma, *Chem. Commun.*, 2012, **48**, 3155–3157.
- 37 G. Cao, X. Jiang, H. Zhang, J. Zheng and T. R. C. J. J. Yin, *J. Environ. Sci. Health, Part C: Environ. Carcinog. Ecotoxicol. Rev.*, 2017, **35**, 223–238.
- 38 D. Pedone, M. Moglianetti, E. De Luca, G. Bardi and P. P. Pompa, *Chem. Soc. Rev.*, 2017, **46**, 4951–4975.
- 39 M. Soh, D. W. Kang, H. G. Jeong, D. Kim, D. Y. Kim, W. Yang, C. Song, S. Baik, I. Y. Choi, S.-K. Ki, H. J. Kwon, T. Kim, C. K. Kim, S.-H. Lee and T. Hyeon, *Angew. Chem., Int. Ed.*, 2017, **56**, 11399–11403.
- 40 Y. Li, X. He, J. J. Yin, Y. Ma, P. Zhang, J. Li, Y. Ding, J. Zhang, Y. Zhao, Z. Chai and Z. Zhang, *Angew. Chem., Int. Ed.*, 2015, **54**, 1832–1835.
- 41 M. Gorecki, Y. Beck, J. R. Hartman, M. Fischer, L. Weiss, Z. Tochner, S. Slavin and A. Nimrod, *Free Radical Res. Commun.*, 2009, **12**, 401–410.
- 42 S. Miriyala, I. Spasojevic, A. Tovmasyan, D. Salvemini, Z. Vujaskovic, D. S. Clair and I. Batinic Haberle, *Biochim. Biophys. Acta*, 2012, **1822**, 794–814.
- 43 P. Prasad, C. R. Gordijo, A. Z. Abbasi, A. Maeda, A. Ip, A. M. Rauth, R. S. DaCosta and X. Y. Wu, *ACS Nano*, 2014, **8**, 3202–3212.
- 44 R. Ragg, A. Schilman, K. Korschelt, C. Wieseotte, M. Kluncker, M. Viel, L. Völker, S. Preiß, J. Herzberger, H. Frey, K. Heinze, P. Blu, F. Natalio and W. Tremel, *J. Mater. Chem. B*, 2016, **4**, 7423–7428.
- 45 N. Singh, M. A. Savanur, S. Srivastava, P. D'Silva and G. Mugesh, *Angew. Chem., Int. Ed.*, 2017, **56**, 14267–14271.
- 46 X. Li, L. Zhou, J. Gao, H. Miao, H. Zhang and J. Xu, *Powder Technol.*, 2009, **190**, 324–326.
- 47 K. Setsukinai, Y. Urano, K. Kakinuma, H. J. Majima and T. Nagano, *J. Biol. Chem.*, 2003, **278**, 3170–3175.
- 48 H. Cheng, S. Lin, F. Muhammad, Y. Lin and H. Wei, *ACS Sens.*, 2016, **1**, 1336–1343.
- 49 J. J. Hu, N.-K. Wong, S. Ye, X. Chen, M.-Y. Lu, A. Q. Zhao, Y. Guo, A. C.-H. Ma, A. Y.-H. Leung, J. Shen and D. Yang, *J. Am. Chem. Soc.*, 2015, **137**, 6837–6843.
- 50 M. Kohno, Y. Mizuta, M. Kusai, T. Masumizu and K. Makino, *Bull. Chem. Soc. Jpn.*, 1994, **67**, 1085–1090.
- 51 Y. Huang, Z. Liu, C. Liu, E. Ju, Y. Zhang, J. Ren and X. Qu, *Angew. Chem., Int. Ed.*, 2016, **55**, 6646–6650.
- 52 S. Kuchera, H. Barth, P. Jacobson, A. Metz, C. Schaechtele and D. Schrier, *Inflammation Res.*, 1993, **39**, C169–C173.

